Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [18F]-FES PET/CT: a Case Report

Ryu, Jeongryul; Jeong, Jae Ho; Moon, Dae Hyuk; Lee, Dong Yun

doi:10.1007/s13139-022-00736-8

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the practice guideline for ER imaging of patients with breast cancer using 18 F-FES PET, approved in June 2023 by Society of Nuclear Medicine and Molecular Imaging (SNMMI)/European Association of Nuclear Medicine (EANM), common clinical indications include: (1) assessing lesions that are difficult to biopsy or yield non-diagnostic results after biopsy, (2) guiding therapy after the progression of metastases, (3) guiding therapy at the initial presentation of metastases, and (4) detecting cancer with ER expression when other imaging tests are equivocal or suspicious for cancer [51,52]. Other emerging indications under investigation are as follows: (1) detecting ER-expressing lesions in patients with suspected or known recurrent or metastatic breast cancer, (2) assessing ER status, instead of biopsy, in lesions that are easily accessible for biopsy, (3) staging invasive lobular breast cancer and low-grade ER-expressing invasive ductal cancer, (4) routinely staging extra-axillary nodes and distant metastases to evaluate ER-expression [53].…”

Section: Estrogen Receptor (Er)mentioning

confidence: 99%

PET/MRI and Novel Targets for Breast Cancer

Chung,

Park,

Lim

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Breast cancer, with its global prevalence and impact on women’s health, necessitates effective early detection and accurate staging for optimal patient outcomes. Traditional imaging modalities such as mammography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging (MRI) play crucial roles in local-regional assessment, while bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) aid in evaluating distant metastasis. Despite the proven utility of 18F-FDG PET/CT in various cancers, its limitations in breast cancer, such as high false-negative rates for small and low-grade tumors, have driven exploration into novel targets for PET radiotracers, including estrogen receptor, human epidermal growth factor receptor-2, fibroblast activation protein, and hypoxia. The advent of PET/MRI, which combines metabolic PET information with high anatomical detail from MRI, has emerged as a promising tool for breast cancer diagnosis, staging, treatment response assessment, and restaging. Technical advancements including the integration of PET and MRI, considerations in patient preparation, and optimized imaging protocols contribute to the success of dedicated breast and whole-body PET/MRI. This comprehensive review offers the current technical aspects and clinical applications of PET/MRI for breast cancer. Additionally, novel targets in breast cancer for PET radiotracers beyond glucose metabolism are explored.

show abstract

Section: Estrogen Receptor (Er)mentioning

confidence: 99%

PET/MRI and Novel Targets for Breast Cancer

Chung,

Park,

Lim

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Therefore, we can try to combine the two and learn from each other's strengths to offset our weaknesses. For example, the physiological uptake of 18 F-FDG in the head is higher, while the uptake of 18 F-FES in the liver is extremely high, so the combination of the two can make up for their respective defects [39] [40] [41]. And due to the existence of ER-negative lesions, the information of 18 F-FESPET/CT imaging alone is limited, so it may be an inevitable trend to combine 18 F-FDGPET/CT at the first examination.…”

Section: A Comparative Study Of Diagnostic Efficiencymentioning

confidence: 99%

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

He,

Pang

2024

JBM

View full text Add to dashboard Cite

Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining 18 F-FES with ER, 18 F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method 18 F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging 18 F-FDG PET/CT in breast cancer.

show abstract

Diagnostic Accuracy of 18F-FES PET/CT for the Detection of Recurrent and Metastatic Breast Cancer

Shin,

Han,

Ryu

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

Purpose To evaluate the diagnostic value of 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) PET/CT for distant metastasis or recurrence in patients with estrogen receptor (ER)–positive breast cancer. Methods Patients with ER-positive breast cancer and suspected of de novo metastasis or recurrence were retrospectively identified from a prospective cohort enrolled for a postmarketing surveillance study of 18F-FES at our institution. Per-patient diagnostic accuracy was assessed using pathology or 2 or more standard-of-care imaging procedures with a minimum of 6 months of follow-up as the reference standard. The per-region detection rate of 18F-FES PET/CT was evaluated and compared with that of standard-of-care imaging. Results Of the 162 included patients, 104 and 58 were suspected to have recurrence or de novo metastasis, respectively. The overall sensitivity and specificity of 18F-FES PET/CT were 95% (95% confidence interval [CI], 89%–98%) and 89% (95% CI, 76%–96%), respectively. When stratified according to clinical settings, the sensitivity and specificity were 95% (95% CI, 88%–99%) and 96% (95% CI, 78%–100%), respectively, for detecting recurrence, and 94% (95% CI, 81%–99%) and 82% (95% CI, 60%–95%) for detecting distant metastasis. In region-based analysis, the overall detection rate of 18F-FES PET/CT was significantly higher than that of standard-of-care imaging (92% [95% CI, 89%–94%] vs 83% [95% CI, 79%–87%], P < 0.001). Conclusions 18F-FES PET/CT showed excellent diagnostic performance in patients with ER-positive breast cancer suspected of de novo metastasis or recurrence.

show abstract

Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [18F]-FES PET/CT: a Case Report

Cited by 3 publications

References 14 publications

PET/MRI and Novel Targets for Breast Cancer

PET/MRI and Novel Targets for Breast Cancer

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

Diagnostic Accuracy of 18F-FES PET/CT for the Detection of Recurrent and Metastatic Breast Cancer

Contact Info

Product

Resources

About

Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [18F]-FES PET/CT: a Case Report

Cited by 3 publications

References 14 publications

PET/MRI and Novel Targets for Breast Cancer

PET/MRI and Novel Targets for Breast Cancer

&lt;sup&gt;18&lt;/sup&gt;F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

Diagnostic Accuracy of 18F-FES PET/CT for the Detection of Recurrent and Metastatic Breast Cancer

Contact Info

Product

Resources

About

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer